Cybin (HELP) Equity Ratio (2021 - 2023)

Cybin (HELP) reported Equity Ratio of 0.9 for Q1 2023, down 2.11% quarter-over-quarter from 0.92 in Q2 2021.

Cybin (HELP) Equity Ratio (2021 - 2023) Analysis & Trends

Cybin has reported Equity Ratio for 2 years, with the latest figure at 0.9 in Q1 2023.

For the quarter ending Q1 2023, Equity Ratio changed N/A year-over-year to 0.9; the trailing twelve-month figure through Feb 2023 stood at 0.9 (changed N/A YoY), and the FY2023 full-year result was 0.9, changed N/A from the prior year.
Equity Ratio for Q1 2023 stood at 0.9, down from 0.92 in the prior quarter.
The five-year high for Equity Ratio was 0.93 in Q1 2021, with the low at 0.9 in Q1 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Ratio (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	191.07
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	0.98
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	0.04
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.58
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	0.42
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	0.73
9	Abivax	91.96 Bn	91.96 Bn	-	0.79
10	Cybin	75.42 Mn	75.42 Mn	-	-

Historic Data

Download Data

Date	Value
Feb 28, 2023	0.90
Jun 30, 2021	0.92
Mar 31, 2021	0.93